DYN Dyne Therapeutics, Inc. Stock Quote

DYN [NASD]

Index	-	P/E	-	EPS (ttm)	-3.54	Insider Own	1.00%	Shs Outstand	51.68M	Perf Week	9.00%
Market Cap	608.25M	Forward P/E	-	EPS next Y	-3.74	Insider Trans	-2.29%	Shs Float	50.97M	Perf Month	16.98%
Income	-182.30M	PEG	-	EPS next Q	-0.92	Inst Own	-	Short Float	1.72%	Perf Quarter	114.87%
Sales	-	P/S	-	EPS this Y	-122.50%	Inst Trans	1.69%	Short Ratio	4.42	Perf Half Y	72.02%
Book/sh	5.55	P/B	2.16	EPS next Y	-11.50%	ROA	-45.00%	Target Price	24.83	Perf Year	-30.81%
Cash/sh	5.75	P/C	2.08	EPS next 5Y	-	ROE	-51.90%	52W Range	4.30 - 17.89	Perf YTD	0.84%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-32.98%	Beta	-
Dividend %	-	Quick Ratio	11.60	Sales past 5Y	-	Gross Margin	-	52W Low	178.84%	ATR	0.82
Employees	108	Current Ratio	11.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	67.09	Volatility	7.06% 7.97%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-73.00%	Profit Margin	-	Rel Volume	1.80	Prev Close	12.05
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 04 BMO	Payout	-	Avg Volume	198.35K	Price	11.99
Recom	1.70	SMA20	9.10%	SMA50	42.14%	SMA200	26.34%	Volume	356,833	Change	-0.50%

Jul-20-22

Initiated

Chardan Capital Markets

Buy

$17

Jul-12-22

Initiated

Raymond James

Outperform

$15

Oct-12-20

Initiated

Stifel

Buy

$29

Oct-12-20

Initiated

Piper Sandler

Overweight

$34

Oct-12-20

Initiated

JP Morgan

Overweight

$27

Oct-12-20

Initiated

Jefferies

Buy

$47

Aug-10-22 07:30AM	Dyne Therapeutics Announces Breakthrough Article Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research GlobeNewswire +7.75%
Aug-04-22 07:30AM	Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights GlobeNewswire
Jul-18-22 10:00AM	Best Momentum Stocks to Buy for July 18th Zacks -5.56%
Jul-12-22 02:54PM	Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew Benzinga +5.94%
07:30AM	Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 GlobeNewswire
Jul-05-22 07:30AM	Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire +17.22%
Jul-01-22 06:58AM	Will Dyne Therapeutics (NASDAQ:DYN) Spend Its Cash Wisely? Simply Wall St.
Jun-03-22 07:30AM	Dyne Therapeutics to Present at Jefferies Global Healthcare Conference GlobeNewswire +5.05%
May-16-22 07:30AM	Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown GlobeNewswire
May-02-22 04:05PM	Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights GlobeNewswire +6.77%
Mar-17-22 08:45AM	selfologi Chooses Digital Technology Consulting Partner Grid Dynamics to Launch Its Cosmetic Treatment Platform ACCESSWIRE
Mar-10-22 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights GlobeNewswire
Mar-03-22 07:30AM	Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors GlobeNewswire
Feb-02-22 01:38PM	HC Advisors, LLC Buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, ... GuruFocus.com -8.68%
Jan-22-22 08:06AM	We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely Simply Wall St.
Jan-18-22 04:18PM	Why Shares of Dyne Therapeutics Dropped 18.1% on Tuesday Motley Fool -12.59%
08:00AM	Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy GlobeNewswire
Jan-05-22 07:30AM	Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire -5.93%
Dec-03-21 03:30PM	Dyne Therapeutics (DYN) Submits IND to FDA for DMD Candidate Zacks +5.94%
Dec-02-21 08:30AM	Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy GlobeNewswire
Nov-04-21 07:30AM	Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights GlobeNewswire
Oct-26-21 10:41AM	Where Do Hedge Funds Stand On Dyne Therapeutics, Inc. (DYN)? Insider Monkey
Oct-13-21 07:45AM	Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day GlobeNewswire
Oct-01-21 10:21AM	Dyne Therapeutics Highlights New Preclinical Data For Duchenne Muscular Dystrophy Program Benzinga
07:30AM	Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin Expression GlobeNewswire
Sep-28-21 07:30AM	Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021 GlobeNewswire +6.48%
Sep-27-21 07:30AM	Dyne Therapeutics to Present at Chardans Virtual 5th Annual Genetic Medicines Conference GlobeNewswire
Sep-20-21 07:30AM	Dyne Therapeutics Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robust Splicing Correction During World Muscle Society 2021 Virtual Congress GlobeNewswire
Aug-05-21 07:30AM	Dyne Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights GlobeNewswire
Jul-26-21 03:00AM	We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth Simply Wall St.
Jun-25-21 07:30AM	Dyne Therapeutics Presents Preclinical Data from its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress GlobeNewswire
Jun-02-21 04:05PM	Dyne Therapeutics Announces Chief Scientific Officer Transition GlobeNewswire
May-26-21 07:30AM	Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference GlobeNewswire
May-14-21 02:44PM	Dyne Therapeutics' Myotonic Dystrophy Gene Therapy Shows Encouraging Action In Animal Studies Benzinga
07:00AM	Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting Demonstrating Sustained Knockdown of Toxic Human Nuclear DMPK RNA GlobeNewswire
May-06-21 07:29AM	Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights GlobeNewswire
Apr-27-21 04:35PM	New Preclinical Data from Dyne Therapeutics Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of Gene & Cell Therapy Annual Meeting GlobeNewswire
Mar-04-21 07:35AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights GlobeNewswire -5.88%
07:25AM	Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer GlobeNewswire
Feb-08-21 07:30AM	Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs GlobeNewswire
Jan-27-21 01:13AM	Here's What Dyne Therapeutics, Inc.'s (NASDAQ:DYN) Shareholder Ownership Structure Looks Like Simply Wall St.
Jan-20-21 08:05PM	Dyne Therapeutics Announces Pricing of $168 Million Public Offering GlobeNewswire
Jan-10-21 03:00PM	Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study GlobeNewswire
Jan-05-21 07:30AM	Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-08-20 10:17AM	Cerevance Appoints David Lubner to Board of Directors GlobeNewswire
Nov-09-20 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Nov-05-20 07:35AM	Dyne Therapeutics Reports Third Quarter 2020 Financial Results and Recent Highlights GlobeNewswire
Oct-09-20 03:41PM	Janus Henderson and PMV Pharmaceuticals See Activist Action Barrons.com
Sep-21-20 04:05PM	Dyne Therapeutics Announces Closing of Initial Public Offering GlobeNewswire
Sep-16-20 07:00PM	Dyne Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire
Dec-13-19 03:38PM	Vistra Operations Company LLC -- Moody's upgrades Vistra's CFR to Ba1 from Ba2, outlook positive Moody's

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Scalzo Richard William	See Remarks	Mar 11	Sale	8.73	308	2,689	26,994	Mar 14 05:09 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Mar 11	Sale	8.73	765	6,678	73,003	Mar 14 05:08 PM
McNeill Jonathan	See Remarks	Mar 11	Sale	8.73	481	4,199	60,466	Mar 14 05:09 PM
Brumm Joshua T	See Remarks	Mar 11	Sale	8.73	3,384	29,542	210,324	Mar 14 05:07 PM
Farwell Wildon	Chief Medical Officer	Mar 11	Sale	8.73	640	5,587	66,050	Mar 14 05:08 PM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 11	Sale	8.73	693	6,050	53,676	Mar 14 05:06 PM
Farwell Wildon	Chief Medical Officer	Mar 02	Sale	8.56	5,617	48,082	66,690	Mar 03 07:22 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Sep 23	Sale	17.22	2,451	42,206	33,453	Sep 24 10:50 AM
McNeill Jonathan	See Remarks	Sep 21	Sale	16.11	729	11,744	35,636	Sep 22 08:02 PM
Brumm Joshua T	See Remarks	Sep 21	Sale	16.11	4,584	73,848	99,018	Sep 22 08:02 PM
Beskrovnaya Oxana	Chief Scientific Officer	Sep 21	Sale	16.11	827	13,323	17,845	Sep 22 08:01 PM
Scalzo Richard William	See Remarks	Sep 21	Sale	16.11	492	7,926	10,606	Sep 22 08:03 PM
Scalzo Richard William	See Remarks	Sep 20	Sale	15.61	367	5,729	11,098	Sep 22 08:03 PM
Beskrovnaya Oxana	Chief Scientific Officer	Sep 20	Sale	15.61	617	9,631	18,672	Sep 22 08:01 PM
Brumm Joshua T	See Remarks	Sep 20	Sale	15.61	3,425	53,464	103,602	Sep 22 08:02 PM
McNeill Jonathan	See Remarks	Sep 20	Sale	15.61	545	8,507	36,365	Sep 22 08:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience